However, clinical trials with proprotein convertase subtilisin/kexin type 9 inhibitors in patients with atherosclerotic vascular disease [10, 11] have shown that hypercholesterolemia in humans should be defined in terms of plasma cholesterol levels that are much lower than previously accepted. This evidence concerns the gene PCSK9 and Hypercholesterolemia.